Analysis demonstrates point-of-care testing for lipoprotein(a) improves cardiovascular risk assessment, suggesting enhanced accessibility.
Background: Lipoprotein(a) is an atherogenic particle and cardiovascular risk factor. 1 Some guidelines recommend testing at least once in the lifetime of an individual, yet testing rates remain low. 2,3 Limited test availability may be a contributing factor to this. In this study, the analytical performance of a point-of-care lipoprotein(a) measurement device (iProtin) was compared with two laboratory assay platforms (Randox and Roche).
No takes yet. Share an insight, caveat, or question.
Bachmeier et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: